Founded in 1994, Adolor Corporation (Nasdaq: ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The overall goal of the company's research effort is to develop products which maintain or improve opioid-like pain relief while reducing or eliminating opioid side effects.
AFx, Inc. developed and marketed catheter-based, microwave ablation systems for minimally invasive treatment of major cardiac arrhythmias. AFx was acquired by Guidant in February of 2004.
Santa Monica, CA
Agensys discovered and developed therapeutic human monoclonal antibodies to treat solid tumor cancers based on its proprietary targets. The Company discovered and validated a large portfolio of novel clinically relevant targets in prostate, bladder, pancreatic and kidney cancer. Agensys was acquired by Astellas Pharma, Inc. in December of 2007.
La Jolla, CA
Angiosyn, Inc. is a biopharmaceutical company developing novel proprietary biologics for controlling angiogenesis. The company's initial therapeutic indication is for ophthalmic diseases, such as macular degeneration and diabetic retinopathy, which due to angiogenesis can lead to decreased vision and blindness. Angiosyn was acquired by Pfizer in January of 2005.
|Arrow Therapeutics Ltd.|
Arrow Therapeutics utilizes its genome-based target discovery technology to search for novel anti-microbial compounds. The Company is focused on unexplored targets for antibiotics, anti-viral, and anti-fungal therapies and aims to overcome the rapidly growing problem of microbial resistance.
|ATS Medical, Inc.|
ATS Medical, Inc. is a leading developer, manufacturer and marketer of products and services focused on cardiac surgery. Nasdaq: ATSI.
ATS was acquired by Medtronic in August of 2010.
|Avid Radiopharmaceuticals, Inc.|
Avid Radiopharmaceuticals is a leader in the development of molecular imaging products that allow for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Avid was acquired by Eli Lilly (NYSE: LLY) in 2010.
Calistoga Pharmaceuticals is a drug discovery company focused on the development of products for the treatment of cancer and inflammatory diseases. Calistoga was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) in 2011.
Cellective Therapeutics was a biopharmaceutical company focused on developing monoclonal antibodies for the treatment of oncology and autoimmune diseases such as B-cell lymphoma, Crohn’s disease and rheumatoid arthritis. The Company was founded in 2003 by Dr. Tom Tedder, Chairman of the Department of Immunology at Duke University, and based on technology licensed from Duke University and the Dana Farber Cancer Institute. Cellective was acquired by MedImmune in September of 2005.
Melbourne, Australia and Menlo Park, CA
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing personalized therapeutics in the areas of oncology, diabetes and obesity. ChemGenex was acquired by Cephalon, Inc. in 2011.
Palo Alto, CA
Connetics Corporation (Nasdaq: CNCT) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market.
South San Francisco, CA
CoTherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the potential treatment of cardiopulmonary and other chronic diseases. CoTherix’s lead product, Ventavis (iloprost) was approved in December 2004 and launched in March 2005 for the treatment of pulmonary arterial hypertension, or PAH, in patients with New York Heart Association Class III or IV symptoms (WHO Group I). CoTherix was purchased by Actelion for $13.50 per share in 2006.
Leiden, The Netherlands
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases.
Cutera, Inc.® (Nasdaq: CUTR) develops, manufactures, and markets laser hair removal systems for dermatologists, plastic surgeons and other practitioners in clinics and offices worldwide.
deCODE genetics (Nasdaq: DCGN) is a population-based genomics company conducting research into the inherited causes of common diseases. Together with pharmaceutical companies and other healthcare institutions, deCODE aims to utilize its research to develop new methods for identifying, treating and preventing disease.
Definity Health, founded in 1999, is a national market leader in consumer-driven health benefit programs. The company was acquired by UnitedHealth Group (NYSE: UNH) in December of 2004.
Diatide, Inc. was founded as a private radiodiagnostic company and in 1999 became Diatide Research Laboratories, a division of Berlex Laboratories focused on developing and making specialized medicines. Diatide was a pioneer in the imaging marketplace, specializing in peptide engineering, molecular biology and radiolabeling chemistry to develop disease-specific diagnostic and therapeutic agents.
Dynavax Technologies (Nasdaq: DVAX) is a biopharmaceutical company developing products to treat allergy, inflammation-mediated diseases, infectious diseases and cancer. The Company's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
San Diego, CA
Endonetics, Inc. developed advanced, minimally invasive medical devices for the diagnosis and treatment of gastrointestinal disorders. The company was acquired by Medtronic, Inc. (MDT: NYSE) in December of 2001.
Ann Arbor, MI
Esperion developed therapeutics for the treatment of cardiovascular diseases. in 2003, Pfizer agreed to buy Esperion for $1.3 billion.
Contact: Dan Janney
New York, NY
Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME). Eyetech was sold to OSI Pharmaceuticals in 2005.
Flamel Technologies S.A. (Nasdaq: FLML) is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins.
|FoldRx Pharmaceuticals, Inc.|
FoldRx Pharmaceuticals is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis). The Company’s lead product, FX-4006, has fully enrolled a Phase II/III study in familial amyloid polyneuropathy.
FoldRx was acquired by Pfizer in October of 2010
Guilford Pharmaceuticals discovered, developed and marketed pharmaceutical products, targeting the hospital and neurological markets. The company was acquired by MGI Pharma (Nasdaq: MOGN), an oncology and acute care focused biopharmaceutical company, in October of 2005.
San Antonio, TX
ILEX Oncology, Inc. was a drug development company focused exclusively on the accelerated development of drugs for the treatment and prevention of cancer. ILEX was acquired by Genzyme Corporation (Nasdaq: GENZ) in 2004.
Intermune, Inc. (Nasdaq: ITMN) is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. The company markets Actimmune® (interferon gamma-1b), approved for the treatment of severe, malignant steopetrosis and chronic granulomatous disease.
|Kerberos Proximal Solutions, Inc.|
Kerberos Proximal Solutions developed and commercialized innovative medical devices for the removal of thrombus from occluded arteries. The Company was acquired by FoxHollow Technologies (Nasdaq:FOXH) in August of 2006.
|Kosan Biosciences, Inc.|
Kosan Biosciences was an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.
Nasdaq: KOSN. Kosan was acquired by Bristol-Myers Squibb (BMY) in May of 2008.
LJL Biosystems, Inc. developed and manufactured automated instrumentation systems for clinical, research and drug development applications. The company was acquired by Molecular Devices Corporation (Nasdaq: MDCC) in August of 2000.
Ft. Lauderdale, FL
MAKO Surgical Corp. (Nasdaq:MAKO) is a medical device company focused on marketing its advanced robotic-arm solution and its implants for minimally invasive orthopedic knee procedures known as MAKOplasty®
Contact: Dan Janney
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including Nexavar with Bayer Pharmaceuticals Corporation.
Orphan Medical is a specialty pharmaceutical company which acquires, develops, and markets pharmaceuticals for inadequately treated and uncommon diseases, including sleep disorders. The Company recently received regulatory approval in the United States for Xyrem, a therapeutic for the treatment of cataplexy. Orphan Medical was a public company traded on Nasdaq under the symbol ORPH. Orphan Medical was sold to Jazz Pharmaceuticals in 2005.
Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. The Company has clinical and preclinical stage programs in several therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease. Plexxikon was acquired by Daiichi Sankyo in 2011.
South San Francisco, CA
Renovis discovers and develops biopharmaceuticals for the treatment of neurological and inflammatory diseases and disorders. The Company uses a combination of novel genomics and cell-based assay technologies coupled with expertise in neurobiology for the discovery of validated targets and the development of small molecules and protein therapeutics.
South San Francisco, CA
Rigel discovers and develops small molecule drugs based on its rapid drug target identification and validation technology. Rigel's technology is designed to identify and validate molecules which play an important role in regulating a human cell's response to disease. Rigel is currently testing its first product, a small molecule drug to treat allergic rhinitis, in clinical trials. Rigel is a public company that trades on Nasdaq under the symbol RIGL.
Redwood City, CA
SurgRx developed and commercialized an advanced tissue sealing and hemostasis system. The Company was acquired by Ethicon Endo-Surgery, and Johnson & Johnson subsidiary, in October of 2008.
|Syntonix Pharmaceuticals, Inc.|
Syntonix Pharmaceuticals developed methods of pulmonary and potentially oral delivery of large molecules through a natural, readily accessible biological pathway, eliminating the need for injections and potentially reducing dosing frequency. The Company was acquierd by Biogen Idec in February of 2007.
|Taligen Therapeutics, Inc.|
Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. Taligen was acquired by Alexion Pharmaceuticals (NASDAQ: ALXN) in 2011
Palo Alto, CA
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases.
|The Medicines Company|
The Medicines Company (Nasdaq: MDCO) meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax® (bivalirudin) for injection, an anticoagulant approved for use in patients undergoing coronary angioplasty procedures.
|U3 Pharma AG|
U3 Pharma AG was advancing a portfolio of novel antibody-based therapeutics to be used as mono therapies and combination therapies for the treatment of cancer. The two lead antibodies were potential therapies for breast, lung and colorectal cancers, among others. U3 Pharma was acquired by Daiichi-Sankyo in June of 2008
Past Performers - Life Sciences
- July 23, 2014
U.S. Food and Drug Administration Approves Gilead's Zydelig® (Idelalisib)For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma--Calistoga acquisition
- December 23, 2013
Esperion Therapeutics Added to the NASDAQ Biotechnology Index
- November 18, 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR™
- November 18, 2013
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance
- September 03, 2013
Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia
- June 26, 2013
Esperion Therapeutics, Inc. Announces Pricing of Initial Public Offering
- June 14, 2013
BioWorld Today: Financings Roundup- Esperion Therapeutics
- May 11, 2013
BioWorld Today: News to Note--Flamel Technologies Inc.
- May 02, 2013
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43